Apogee Therapeutics, Inc. (APGE) Tuesday announced positive interim data from the Phase 1 study of its lead drug APG777 to treat moderate-to-severe atopic dermatitis (AD) and other inflammatory diseases.
The phase 1 study was designed to evaluate safety and Pharmacokinetic (PK) of APG777 in healthy volunteers.
PK data from the study showed a half-life of approximately 75 days across doses tested, requiring less frequent injections. Pharmacodynamic (PD) data showed deep and sustained inhibition of key AD biomarkers pSTAT6 and TARC for nearly 3 months.
The company plans to initiate a Phase 2 study of APG777in patients with moderate-to-severe atopic dermatitis in the first half of 2024.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.